Floatz logo

Maraviroc

Acute Leukemia

National Heart, Lung, and Blood Institute (NHLBI)Small moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

60 Active assets in the Acute Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Sawa Ito, MD
Phase 2/3BB
Cyclophosphamide
Sawa Ito, MD
Phase 4BB
Cytosin-Arabinosid
Janssen Research & Development, LLC
Phase 2/3BB
METHOTREXATE
SWOG Cancer Research Network
Phase 3BB
Busulphan
Sawa Ito, MD
Phase 4BB

View all 50 →

Same molecule, other indications

Maraviroc is also rated in:

HIV infectious diseaseDormant
B
Indicative ·
62 / 100
View asset →
chronic myeloid leukemiaDormant
B
Indicative ·
57 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →